Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis

Alimentary Pharmacology and Therapeutics

Volumn 45, Issue 2, 2017, Pages 319-331

  Acharya, C ^a   Betrapally, N S ^b   Gillevet, P M ^b   Sterling, R K ^a   Akbarali, H ^a   White, M B ^a   Ganapathy, D ^a   Fagan, A ^a   Sikaroodi, M ^b   Bajaj, J S ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 6; OPIATE; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; BACTEROIDACEAE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG USE; END STAGE LIVER DISEASE; ENDOTOXEMIA; FEMALE; HOSPITAL READMISSION; HUMAN; INFLAMMATION; INTESTINE FLORA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POPULATION ABUNDANCE; PREDICTION; PRIORITY JOURNAL; SYSTEMIC DISEASE; DRUG EFFECTS; DYSBIOSIS; FECES; HEPATIC ENCEPHALOPATHY; HOSPITAL DISCHARGE; MICROBIOLOGY; MIDDLE AGED; STATISTICS AND NUMERICAL DATA;

ANALGESICS, OPIOID; DYSBIOSIS; ENDOTOXEMIA; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PATIENT DISCHARGE; PATIENT READMISSION;

EID: 85002410356     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13858     Document Type: Article

References (27)

1. Website at Department of Health and Human Services http://www.hhs.gov/sites/default/files/Factsheet-opioids-061516.pdf. Accessed 1 August 2016.
2. Rogal SS, Winger D, Bielefeldt K, Szigethy E. Pain and opioid use in chronic liver disease. Dig Dis Sci 2013; 58: 2976–85.
3. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008; 64: 1147–61.
4. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014; 60: 715–35.
5. Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis – a practical guide. Aliment Pharmacol Ther 2013; 37: 1132–56.
6. Banerjee S, Sindberg G, Wang F, et al. Opioid-induced gut microbial disruption and bile dysregulation leads to gut barrier compromise and sustained systemic inflammation. Mucosal Immunol 2016; 9: 1418–28
7. Meng J, Banerjee S, Li D, et al. Opioid exacerbation of Gram-positive sepsis, induced by gut microbial modulation, is rescued by IL-17A neutralization. Sci Rep 2015; 5: 10918.
8. Rogal SS, Bielefeldt K, Wasan AD, et al. Inflammation, psychiatric symptoms, and opioid use are associated with pain and disability in patients with cirrhosis. Clin Gastroenterol Hepatol 2015; 13: 1009–16.
9. Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014; 60: 940–7.
10. Bajaj JS, Betrapally NS, Gillevet PM Decompensated cirrhosis and microbiome interpretation. Nature 2015; 525: E1–2.
11. Gillevet P, Sikaroodi M, Keshavarzian A, Mutlu EA. Quantitative assessment of the human gut microbiome using multitag pyrosequencing. Chem Biodivers 2010; 7: 1065–75.
12. Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation. Genome Biol 2011; 12: R60.
13. Langille MG, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol 2013; 31: 814–21.
14. Bergasa NV, Rothman RB, Mukerjee E, Vergalla J, Jones EA. Up-regulation of central mu-opioid receptors in a model of hepatic encephalopathy: a potential mechanism for increased sensitivity to morphine in liver failure. Life Sci 2002; 70: 1701–8.
15. Yurdaydin C, Karavelioglu D, Onaran O, Celik T, Yasa MH, Uzunalimoglu O. Opioid receptor ligands in human hepatic encephalopathy. J Hepatol 1998; 29: 796–801.
16. Tapper EB, Halbert B, Mellinger J. Rates of and reasons for hospital readmissions in patients with cirrhosis: a multistate population-based cohort study. Clin Gastroenterol Hepatol 2016; 14: 1181–8.e2.
17. Kanwal F, Asch SM, Kramer JR, Cao Y, Asrani S, El-Serag HB. Early outpatient follow-up and 30-day outcomes in patients hospitalized with cirrhosis. Hepatology 2016; 64: 569–81.
18. Babrowski T, Holbrook C, Moss J, et al. Pseudomonas aeruginosa virulence expression is directly activated by morphine and is capable of causing lethal gut-derived sepsis in mice during chronic morphine administration. Ann Surg 2012; 255: 386–93.
19. Shawcross DL. Is it time to target gut dysbiosis and immune dysfunction in the therapy of hepatic encephalopathy? Expert Rev Gastroenterol Hepatol 2015; 9: 539–42.
20. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008; 28: 26–42.
21. Bajaj JS, Betrapally NS, Hylemon PB, et al. Gut microbiota alterations can predict hospitalizations in cirrhosis independent of diabetes mellitus. Sci Rep 2015; 5: 18559.
22. Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016; 63: 764–75.
23. Nava GM, Stappenbeck TS. Diversity of the autochthonous colonic microbiota. Gut Microbes 2011; 2: 99–104.
24. Wieland A, Frank DN, Harnke B, Bambha K. Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2015; 42: 1051–63.
25. Vassallo G, Mirijello A, Ferrulli A, et al. Review article: alcohol and gut microbiota – the possible role of gut microbiota modulation in the treatment of alcoholic liver disease. Aliment Pharmacol Ther 2015; 41: 917–27.
26. DuPont HL. Review article: the antimicrobial effects of rifaximin on the gut microbiota. Aliment Pharmacol Ther 2016; 43(Suppl 1): 3–10.
27. Website describing rifaximin prescribing information at the FDA. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022554lbl.pdf. Accessed 1 August 2016.